AstraZeneca announced that 54 abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, 14-18 September 2015.
The presentations will include data on a number of approved products for the treatment of type 2 diabetes, including Forxiga® (dapagliflozin), Onglyza® (saxagliptin), Bydureon® (once-weekly exenatide extended-release for injectable suspension) and Byetta® (exenatide) injection, as well as data on the investigational combination of saxagliptin and dapagliflozin, which is currently being reviewed by the regulatory authorities in the US and EU. Additionally, several abstracts representing AstraZeneca’s early stage and pre-clinical research explore novel pathways and modalities to address the underlying pathophysiology of diabetes.
Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, said: “The breadth and depth of research we’re presenting at EASD demonstrates our continuous commitment to developing innovative diabetes treatments. We believe these data reinforce our focus to help healthcare providers and patients with type 2 diabetes reach treatment goals sooner.”
